The campaign bridges past and present by recreating 10 original protest banners from the first Pride marches, returning them to the streets in 2025.A powerful call to defend hard-won rights under threat: over 90 legal rollbacks in the past three years, 62 countries still criminalize homosexuality, and marriage equality is recognized in only 38.The project, which honors those who ignited the fight for LGBTQ+ rights, was made possible through a collaboration with the production company Dim Sum and the support ...

In the latest trading session, Cadence Design Systems (CDNS) closed at $296.80, marking a +1.1% move from the previous day. This move lagged the S&P 500's daily gain of 1.11%. Elsewhere, the Dow saw an upswing of 1.19%, while the tech-heavy Nasdaq appreciated by 1.43%. The stock of maker of hardware and software products for validating chip designs has fallen by 6.96% in the past month, lagging the Computer and Technology sector's gain of 5.67% and the S&P 500's gain of 3.92%.Market participants will be clo ...

WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed’s unique position as the world’s only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device ...

Core Viewpoint - Brady Corporation reported strong financial results for the third quarter of fiscal 2025, with significant sales growth driven by acquisitions and organic growth in the Americas and Asia regions, despite challenges from foreign currency translation [2][8]. Financial Results - Sales for the third quarter ended April 30, 2025, were $382.6 million, an increase of 11.4% from $343.4 million in the same quarter last year. This growth included organic sales growth of 1.6%, acquisition-related growth of 10.5%, and a decline of 0.7% due to foreign currency translation [2][4]. - For the nine-month period ended April 30, 2025, sales increased by 11.9% to $1.12 billion from $998.0 million in the same period last year, with organic growth of 2.6% and acquisition growth of 10.2% [5][7]. Income Metrics - Income before income taxes for the third quarter increased by 2.1% to $65.7 million compared to $64.4 million in the same quarter last year. Adjusted income before income taxes rose by 11.5% to $74.4 million [3][6]. - Net income for the third quarter was $52.3 million, up from $50.9 million in the same quarter last year. Adjusted net income increased to $58.8 million from $52.7 million [4][7]. Earnings Per Share - Earnings per diluted Class A Nonvoting Common Share for the third quarter was $1.09, compared to $1.05 in the same quarter last year, reflecting a 3.8% increase. Adjusted diluted EPS reached a record high of $1.22, up 11.9% from $1.09 [4][29]. Regional Performance - Sales in the Americas and Asia increased by 12.9%, with organic growth of 5.4%. In contrast, sales in Europe and Australia grew by 8.7%, but organic sales declined by 5.4% [2][5]. Shareholder Returns - The company returned $44.5 million to shareholders through dividends and share repurchases during the quarter, including repurchasing 476,000 shares for $33.2 million [8][9]. Fiscal Guidance - The company tightened its Adjusted Diluted EPS guidance for the fiscal year ending July 31, 2025, to a range of $4.48 to $4.63 per share, and updated GAAP earnings guidance to $3.95 to $4.10 per share [10][11].

Forward-Looking Statements This presentation contains certain "forward-looking statements" with respect to our financial condition, results of operations, profitability, margin growth, business strategies, operating efficiencies or synergies, competitive position, growth opportunities, acquisitions, plans and objectives of management, markets for the Company's common stock, the impact of legal proceedings, and other matters. Statements in this presentation that are not historical facts are "forward-looking ...

Financial Data and Key Metrics Changes - For Q1 2025, the company achieved revenue of $19.5 million, an 11% increase from $17.6 million in Q1 2024 [4][11] - Gross profit margin was reported at 76.1%, consistent with Q1 2024 [12] - GAAP diluted earnings per share increased by 16% to $0.37 from $0.32 in Q1 2024 [13] - Non-GAAP adjusted net income was $5.3 million or $0.42 per diluted share, up 17% from $4.6 million or $0.36 per diluted share in Q1 2024 [14] Business Line Data and Key Metrics Changes - Revenue from IV infusion pump systems grew 16% to $6 million, while disposable revenue increased 23% to $4.9 million [11][12] - Patient vital signs monitoring systems revenue remained steady at $6.5 million [12] - Domestic sales accounted for 82% of total revenue, up from 76% in Q1 2024, with domestic revenue increasing 19% to $16 million [12] Market Data and Key Metrics Changes - International sales declined 15% to $3.5 million [12] - Device revenue increased 9% to $13 million, driven by pump revenue and FMD systems [12] Company Strategy and Development Direction - The company is focused on increasing monitoring sales in 2025, anticipating a decline in pump revenues later in the year [21] - The new 3,870 MRIV pump is expected to be a revenue driver in 2026, with clearance anticipated in mid-2025 [9][10] - The company is nearing completion of a new facility, with full operations expected by July 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the impact of tariffs, noting that only 3% of revenue is connected to high tariff sources [6][7] - The FDA's responsiveness has been positive, with ongoing interactions indicating progress towards device clearance [25][27] - The company expects Q2 2025 revenue guidance of $19.7 million to $19.9 million, reiterating full-year revenue guidance of $78 million to $82 million [10] Other Important Information - Operating expenses were $9.4 million, or 48% of revenue, down from 49% in Q1 2024 [12] - Cash flow from operations was $4.3 million, up 10% from $3.9 million in Q1 2024 [14] Q&A Session Summary Question: Any anomalies in disposable revenue growth? - Management indicated that some backlog was worked down in Q1, contributing to the growth, but expects future growth to align with capital growth [17][18] Question: Confidence in monitoring sales recovery? - Management emphasized efforts to boost monitoring sales through adjusted compensation structures, with strong bookings already seen in Q2 [20][22] Question: Status of FDA interactions and clearance timeline? - Management noted ongoing interactive questions from the FDA, suggesting a positive sign, with expectations for clarity in the next three to four weeks [24][27]

Financial Data and Key Metrics Changes - Q1 2025 sales were $181.6 million, a decrease of 1.3% year-over-year, with comparable store sales down 4.8% [3][18] - Gross margins increased to 61.2% from 60.3%, reflecting improved product selection and merchandise mix [4][18] - Pre-tax profits rose to $5.3 million, with an operating margin of 2.9%, compared to $3.2 million and 1.7% in Q1 2024 [4][19] - Net income for Q1 2025 was $3.8 million, or $0.23 per diluted share, compared to $2.4 million, or $0.14 per share in the same quarter last year [19] Business Line Data and Key Metrics Changes - The design business accounted for approximately 33% of total business, with an average ticket of over $3,300, up about 4% [6] - The designer average ticket grew to over $7,400, an increase of over 9% [6] - Weakness was noted in dining and occasional categories, while upholstery, bedroom, and mattress categories performed in line with expectations [6] Market Data and Key Metrics Changes - Written sales were down 2.6% with comparable sales down 6.3% [3] - Sales for Presidents' Day were disappointing, down roughly 10% over the two-week period [5] - Traffic softened but remained positive in the low single digits, with conversion rates stabilizing and showing some improvement compared to last year [5] Company Strategy and Development Direction - The company plans to roll out a new point of purchase and tagging program to enhance the in-store customer experience [7] - The strategy includes increasing inventories of best-selling products to mitigate supply chain disruptions due to tariffs [11][12] - The company aims to open five new stores annually, with a cautious approach based on current market conditions [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with Q1 results despite challenges such as housing market lows, high interest rates, and declining consumer confidence [4][16] - The company is well-positioned to navigate challenges due to its strong brand, debt-free balance sheet, and customer focus [17] - Future guidance includes expectations for gross margins between 60% and 60.5% for 2025, factoring in current tariffs [21][22] Other Important Information - Inventory levels increased by approximately $5 million or about 6% since year-end 2024 [11] - The company has no funded debt and ended Q1 with $111.9 million in cash and cash equivalents [20] - CapEx for Q1 2025 was $6.1 million, with a planned reduction to $24 million for the year due to tariff uncertainties [22] Q&A Session Summary Question: Impact of winter storms on business - Management noted that January was down almost 2% in written business, February down about 5%, and March was flat, with multiple storms impacting operations [26][27][28] Question: Price increases due to tariffs - Management confirmed targeted price increases will be implemented, but they expect minimal impact on consumers due to supplier cooperation [31][32] Question: Changes in competition - Management observed aggressive promotions from competitors but did not believe promotional activity was the primary issue affecting sales [34][35] Question: Reduction in CapEx guidance - Management explained the $3 million reduction in CapEx was due to tariff uncertainties, leading to a cautious approach on store expansion [36][37] Question: Performance of new stores - Management expressed satisfaction with new store performance, noting they leverage existing distribution networks and initial traffic has been good [47][48]

Haverty Furniture Companies (HVT) Q1 2025 Earnings Call May 01, 2025 10:00 AM ET Company Participants Richard Hare - EVP & CFOSteven Burdette - President & CEO Conference Call Participants Anthony Lebiedzinski - Senior Equity Research AnalystCristina Fernández - Managing Director & Senior Equity Research Analyst Operator As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Richard Hare, Chief Financial Officer. Thank you, sir. You may begin. Richard Hare Thank you, ...

Company Overview - IRADIMED CORPORATION is a leader in developing innovative MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company has developed the MRidium® MRI compatible IV infusion pump system, which features a non-magnetic ultrasonic motor and non-ferrous parts to ensure safe and predictable delivery of anesthesia and IV fluids during MRI scans [3]. Product Offerings - The 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - The Iradimed 3880 system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit, facilitating effective communication of vital signs to clinicians [4]. Upcoming Events - The company will release its 2025 first quarter financial results before the market opens on May 5, 2025, followed by a conference call at 9:00 a.m. Eastern Time to discuss the results [1]. - Interested participants can register for the conference call through a provided link, and a recording will be available on the company's website after the call [2].

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ("MRI") compatible medical devices. We are t ...